Business

Announcement on Obtaining the Approval Notice for Drug Clinical Trials of Adsorbed Acellular Pertussis (Components), Tetanus, Diphtheria, Haemophilus Influenzae Type b (Conjugate), and Meningococcal Group ACYW135 (Conjugate) Combined Vaccine

Announcement on Obtaining the Approval Notice for Drug Clinical Trials of Adsorbed Acellular Pertussis (Components), Tetanus, Diphtheria, Haemophilus Influenzae Type b (Conjugate), and Meningococcal Group ACYW135 (Conjugate) Combined Vaccine

articleCansino Biologics, Inc. Class AFebruary 24, 20253/news/announcement-on-obtaining-the-approval-notice-for-drug-clinical-trials-of-adsorbed-acellular-pertussis-components-tetanus-diphtheria-haemophilus-influenzae-type-b-conjugate-and-meningococcal-group-acyw135-conjugate-combined-vaccine
Announcement on Obtaining the Approval Notice for Drug Clinical Trials of Adsorbed Acellular Pertussis (Components), Tetanus, Diphtheria, Haemophilus Influenzae Type b (Conjugate), and Meningococcal Group ACYW135 (Conjugate) Combined Vaccine

About this update from Cansino Biologics, Inc. Class A

Announcement on Obtaining the Approval Notice for Drug Clinical Trials of Adsorbed Acellular Pertussis (Components), Tetanus, Diphtheria, Haemophilus Influenzae Type b (Conjugate), and Meningococcal Group ACYW135 (Conjugate) Combined VaccineThe abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Cansino Biologics, Inc. Class A